# Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients

> **NCT00541385** · PHASE3 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 535 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** pyronaridine artesunate
- **DRUG:** arthemeter lumefantrine

## Key facts

- **NCT ID:** NCT00541385
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-09
- **Final completion:** 2008-11
- **Target enrollment:** 535 (ACTUAL)
- **Last updated:** 2021-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541385, "Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00541385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*